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OBJECTIVES We sought to evaluate whether strut thickness may impact the restenosis rate after stent
implantation in small coronary arteries.
BACKGROUND Small vessel size (3.0 mm) is an independent risk factor for the occurrence of in-stent
restenosis. It has been reported that vessel damage induced during stent deployment is an
important factor in restenosis.
METHODS From our database, we selected all patients who had successful stenting in small native vessels,
with angiographic follow-up available, between March 1996 and April 2001. The strut was
defined as thin when 0.10 mm and thick when 0.10 mm. According to these criteria, we
identified two subgroups: a thin group and a thick group.
RESULTS A total of 821 (57%) of the 1,447 patients had angiographic follow-up available and were
included in the analysis. The thin group included 400 patients with 505 lesions. The thick
group included 421 patients with 436 lesions. The restenosis rate was 28.5% in the thin group
and 36.6% in the thick group (p 0.009; odds ratio [OR] 1.44, 95% confidence interval [CI]
1.09 to 1.90). The study group was classified into three subgroups according to the reference
vessel diameter:2.50 mm, 2.51 to 2.75 mm and 2.76 to 2.99 mm. Strut thickness influenced
the restenosis rate only in the subgroup with a reference vessel diameter between 2.76 and
2.99 mm, with rates of 23.5% in the thin group and 37% in the thick group (p  0.006). By
logistic regression analysis, predictors of restenosis were stent length (OR 1.03, 95% CI 1.01
to 1.04; p  0.001), strut thickness (OR 1.68, 95% CI 1.23 to 2.29; p  0.001) and diabetes
mellitus (OR 2.10, 95% CI 1.21 to 3.68; p  0.007).
CONCLUSIONS This study supports that strut thickness is an independent predictor of restenosis in coronary
arteries with a reference diameter of 2.75 to 2.99 mm. (J Am Coll Cardiol 2002;40:403–9)
© 2002 by the American College of Cardiology Foundation
The restenosis rate after stent implantation is higher in
small (3.0 mm reference diameter) versus large coronary
arteries (1–3). Randomized, observational studies have
found that stent-selected lesions located in small vessels lead
to results equivalent to or better than those achieved with
balloon angioplasty (4–8). Kastrati et al. (9) recently dem-
onstrated that the use of a thinner strut device is associated
with a significant reduction in angiographic and clinical
restenosis after coronary artery stenting in vessels with a
reference diameter 2.8 mm.
The purpose of the present study was to evaluate whether
strut thickness may impact the restenosis rate after stent
implantation in small coronary arteries.
METHODS
Patient group. From March 1996 to April 2001, 2,911
consecutive patients with 3,334 lesions underwent coronary
stent implantation in small (3.0 mm reference diameter)
native coronary arteries in two institutions. All patients with
self-expandable stents (n  57), coil stents (n  208),
covered stents (n  4) radioactive stents (n  100), a
combination of different stents (n  973) and atherectomy
(both rotational and directional; n  81) were excluded
from the analysis. Patients with successful stent placement
and no major adverse cardiac events (MACE) during the
first 30 days after the intervention were considered eligible
for angiographic follow-up. After the exclusion of 65
patients in whom the procedure failed (success rate 96%)
and 75 patients who developed at least one MACE during
the first 30 days (30-day incidence of MACE 4.9%), all
other patients were asked to undergo coronary angiography
at six months or earlier if they had recurrence of symptoms.
Angiographic follow-up was available in 821 (57%) of the
1,447 patients at an average of 8  2 months after the
procedure. Therefore, the final study group included con-
sisted of 821 consecutive patients with 941 lesions success-
fully treated with slotted-tube or multicellular stent implan-
tation, or both, in small coronary arteries. All patients gave
written, informed consent for both the intervention and
follow-up angiography.
Stent implantation procedure. Intracoronary stenting was
performed using techniques previously described (10). All
patients received 325 mg aspirin before stent deployment.
All patients received 70 IU/kg of an intra-arterial bolus of
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unfractionated heparin. Glycoprotein IIb/IIIa inhibitors
were administered according to the operator’s preference.
Definitions. All stents with a strut thickness 0.10 mm
were considered as thin, whereas all stents with a strut
thickness 0.10 mm were considered as thick (11). Thin
stents (thin group) included the Palmaz-Schatz (Cordis,
Johnson & Johnson Company, Warren, New Jersey), ACS
Multilink (Guidant Corp., Santa Clara, California),
Biodyvisio (Biocompatibles Ltd., Surrey, UK), BeStent
(Medtronic, Minneapolis, Minnesota), Jostent Flex (Jomed
International AB, Helsingborg, Sweden), Diamond (Phytis
Medical Devices GmbH, Berlin, Germany), V-Flex (Global
Therapeutic, Inc., Bloomington, Indiana) and Carbostent
(Sorin Biomedica Cardio, Saluggia, Italy). Thick stents
(thick group) included the NIR (Medinol/Scimed Life
Systems, Maple Grove, Minnesota), ACS Duet (Guidant
Corp.), BX Velocity (Cordis, Johnson & Johnson Compa-
ny), AVEII (Medtronic), Crossflex LC (Cordis, Johnson &
Johnson Company) and Bard XT (CR Bard Inc., Billerica,
Massachusetts).
Postprocedural management and follow-up. After suc-
cessful stent implantation was achieved, no further heparin
was administered, and the sheaths were removed in 4 to 6 h.
Aspirin (325 mg/day) and ticlopidine (250 mg twice daily
for 30 days) were prescribed to all patients. Follow-up was
performed in all patients by means of an interview or
telephone conversation with the patient or with the refer-
ring physician. Follow-up angiography was performed at six
months, unless an early re-study was indicated by symp-
toms.
Angiographic measurements were performed, as previ-
ously described, with an automated computer-based system
(QCA-CMS version 3.0, MEDIS, Leiden, The Nether-
lands) (12). The lesions were characterized according to the
modified American College of Cardiology/American Heart
Association classification (13). Angiographic success was de-
fined as final angiographic residual stenosis of 20% by a
visual estimate. Restenosis was defined in a dichotomous
manner as diameter stenosis (DS) 50% at follow-up
angiography. The analysis included assessment of the min-
imal lumen diameter (MLD) and percent DS immediately
after stenting and at follow-up, as well as their cumulative
distributions. According to a continuous geometric model
of restenosis, we examined: 1) acute gain (MLD [after
stenting]  MLD [before procedure]); 2) relative gain
(acute gain/reference diameter before stenting); 3) late loss
(MLD [after stenting] MLD [at follow-up]); and 4) loss
index (late loss/acute gain).
Intravascular ultrasound imaging was performed with a
3.9F monorail system equipped with a 25-MHz transducer-
tipped catheter (Interpret Catheter, Inter-Therapy/CVIS)
or a 2.9F or 3.2F monorail system equipped with a 30-MHz
transducer-tipped catheter (Scimed-Boston Scientific, Ma-
ple Grove, Minnesota).
Statistical analysis. Continuous variables are expressed as
the mean value  SD. Paired and unpaired t tests were
performed to determine the differences between mean
values for baseline continuous variables. The Fisher exact
test was used to analyze categorical variables at baseline. The
study group was classified into three subgroups (tertiles)
according to the reference vessel diameter: 2.50 mm for
the first group; 2.51 to 2.75 mm for the second group; and
2.76 to 2.99 mm for the third group. Angiographic data
were analyzed by a mixed linear model with the interaction
between group (thin and thick), vessel diameter tertiles and
group-by-vessel diameter tertiles as a fixed effect and patient
indicator as a random term to take into account clustered
data (more lesions within the same patient). A comparison
Table 1. Clinical Characteristics of the Two Groups According to Stent Strut Thickness
Thin Group
(n  400)
Thick Group
(n  451)
p
Value
Age (yrs) 59  10 60  10 0.20
Male 354 (88.5%) 381 (84.5%) 0.10
Unstable angina 137 (34.3%) 157 (34.8%) 0.53
Previous MI 204 (51%) 230 (51%) 0.92
LV ejection fraction 56  11% 60  12% 0.28
Previous bypass surgery 40 (10%) 52 (11.5%) 0.48
Systemic hypertension 316 (79%) 360 (80%) 0.96
Diabetes mellitus 44 (11%) 22 (5%) 0.001
Hypercholesterolemia 208 (52%) 225 (50%) 0.83
Smokers (current and former) 160 (60%) 275 (61%) 0.25
Coronary artery disease 0.001
Single-vessel 170 (42.6%) 124 (27.5%)
Double-vessel 148 (37%) 182 (40.4%)
Triple-vessel 82 (20.4%) 145 (32.1%)
Data are presented as the mean value  SD or number (%) of patients.
LV  left ventricular; MI  myocardial infarction.
Abbreviations and Acronyms
CI  confidence interval
DS  diameter stenosis
OR  odds ratio
MACE  major acute cardiac events
MLD  minimal lumen diameter
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of angiographic measurements in the three subgroups was
performed by using proper, mixed linear model contrasts
and by adjusting the p value using the Tukey approach for
multiple comparisons. The SAS Proc Mixed (Cary, North
Carolina) was used to obtain maximal likelihood solutions
of the mixed linear models. The influence of clinical,
angiographic and procedural variables on restenosis was
evaluated by univariate and stepwise logistic regression
analyses. All variables with a p value0.10 in the univariate
analysis were entered into the multivariate model of reste-
nosis to test for independent effects. The analysis was made
per lesion. A p value of 0.05 was considered statistically
significant. Data were analyzed with SPSS version 10.0
(SPSS Inc., Chicago, Illinois) for Windows.
RESULTS
The thin group included 400 patients with 505 lesions.
Thin stents included the Palmaz-Schatz (39.5%), ACS
Multilink (9.2%), Biodyvisio (10.2%), BeStent (10%), Jos-
tent Flex (4%), Diamond (7.6%), V-Flex (5.6%) and Car-
bostent (13.9%). The thick group included 421 patients
with 436 lesions. Thick stents were the NIR (25.5%), ACS
Duet (33.5%), BX Velocity (18%), AVEII (18%), Crossflex
LC (2.8%) and Bard XT (2.2%).
Clinical characteristics. Patients in the thin group were
more often diabetics and had a lower rate of multivessel
disease (Table 1).
Angiographic and procedural characteristics. The refer-
ence artery size was similar between the two groups. In
contrast, there were significant differences in MLD, percent
DS, lesion length, target vessel distribution, lesion type and
lesion site (Table 2). Indeed, the lesions were more often
complex (e.g., B2/C), longer and located in the ostium in
the thick group versus the thin group.
Intravascular ultrasonography was performed more often
in the thin group than in the thick group (63% vs. 33%; p
Table 2. Angiographic Characteristics of the Two Groups According to Stent Strut Thickness
Thin Group
(n  505)
Thick Group
(n  436)
p
Value
Vessel treated 0.002
LAD 260 (51.5%) 162 (38.4%)
LCx 79 (15.6%) 90 (20.6%)
RCA 89 (17.6%) 100 (22%)
Diagonal branch 26 (5.1%) 30 (6.9%)
Intermedial branch 26 (5.1%) 36 (8.3%)
Obtuse marginal branch 16 (3.2%) 7 (1.6%)
Others branches 9 (1.8%) 11 (2.5%)
Lesion site 0.012
Ostial 40 (7.9%) 46 (10.6%)
Proximal 193 (38.2%) 140 (32.1%)
Mid vessel 221 (43.8%) 181 (41.5%)
Distal 51 (10.1%) 69 (15.8%)
Lesion types 0.004
A 22 (4.4%) 21 (4.8%)
B1 168 (33.2%) 103 (23.6%)
B2 209 (41.4%) 196 (44.9%)
C 106 (21%) 116 (26.7%)
Diameter stenosis (%)
Before stenting 68  16 66  17 0.022
After stenting 1  10 1  7 0.80
Follow-up 36  25 40  24 0.005
Bifurcation lesions 105 (21%) 102 (23.5%) 0.33
Chronic total occlusion 30 (6%) 31 (7.2%) 0.45
Lesion length (mm) 11  7 13  9  0.001
Reference diameter (mm)
Before stenting 2.60  0.33 2.58  0.32 0.38
After stenting 2.62  0.36 2.64  0.36 0.38
Follow-up 2.67  0.45 2.61  0.43 0.25
MLD (mm)
Before stenting 0.83  0.41 0.89  0.44 0.018
After stenting 2.52  0.50 2.53  0.50 0.80
Follow-up 1.77  0.80 1.60  0.75 0.005
Acute gain (mm) 2.00  0.60 1.84  0.58  0.001
Relative gain (mm) 0.77  0.22 0.72  0.24 0.002
Late loss (mm) 1.04  0.79 1.16  0.76 0.031
Loss index 0.54  0.43 0.66  0.47  0.001
Data are presented as the mean value  SD or number (%) of patients.
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; MLD  minimal lumen diameter;
RCA  right coronary artery.
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0.001), whereas direct stenting was similar (10%) for both
groups (p  0.90). The balloon-to-artery ratio and inflation
pressure were higher in the thin group than in the thick
group (1.3  0.2 atm vs. 1.2  0.2 atm and 15  3 atm vs.
14  3 atm, respectively; p  0.001 for both). Acute gain
was higher in the thin group, whereas the final MLD was
similar between the two groups (Table 2). The final stent
length was longer in the thin group (20  11 mm vs. 19 
11 mm, p 0.037). Administration of glycoprotein IIb/IIIa
inhibitors was similar between the thin group (17%) and
thick group (16%; p  0.85).
Long-term angiographic outcome. The restenosis rate
was significantly lower in the thin group (28.5%) than in the
thick group (36.6%; p  0.009; odds ratio [OR] 1.44, 95%
confidence interval [CI] 1.09 to 1.90) (Fig. 1). This finding
was also confirmed when deleting from the analysis the
carbon-coated (Carbostent and Diamond) stents (27.6% vs.
34.7%; p 0.016; OR 1.40, 95% CI 1.06 to 1.83). Of note,
the loss index was significantly lower in the thin group
(Table 2). The estimated mean relative surface area coverage
of the vessel (11) was slightly higher in the thin group than
in the thick group (18  2% vs. 17  2%; p  0.001) but
was not different according to restenosis occurrence (17 
3% in case of restenosis vs. 17  3%; p  0.86). Because of
important differences in some clinical and angiographic
characteristics that may potentially impact the restenosis
rate, we identified the independent predictors of restenosis
in our study group. Predictors of restenosis by univariate and
multivariable analyses are summarized in Table 3. By
stepwise logistic regression analysis, predictors of restenosis
in the entire study group were stent length (OR 1.03, 95%
CI 1.01 to 1.04; p  0.001), strut thickness (OR 1.68, 95%
CI 1.23 to 2.29; p  0.001) and diabetes mellitus (OR 2.1,
95% CI 1.21 to 3.68; p  0.007).
To better clarify the impact of strut thickness on reste-
nosis as a function of vessel size, we further analyzed three
subgroups (tertiles) of vessels, according to the reference
diameter: 1) vessel diameter 2.50 mm (300 lesions); 2)
vessel diameter 2.51 to 2.75 mm (291 lesions); and 3) vessel
diameter 2.76 to 2.99 mm (350 lesions) (Tables 4 and 5).
Strut thickness influenced the restenosis rate only in the
subgroup with a reference vessel diameter between 2.76 and
2.99 mm (23.5% in the thin group and 37% in the thick
group; p  0.006; OR 1.91, 95% CI 1.19 to 3.0) (Fig. 2).
As represented in Figure 3, the loss index was similar in
vessels with a reference diameter 2.50 mm, although it
was lower in the thin group, as the reference vessel diameter
increased, and it was statistically lower only in vessels with
a reference diameter between 2.76 and 2.99 mm.
DISCUSSION
The main result of the present study is that strut thickness
appears to be an independent predictor of restenosis after
stent implantation in vessels with a reference diameter3.0
mm. The implantation of stents with a thin (0.10 mm)
strut may reduce the restenosis rate in small coronary
arteries. In particular, implantation of thin-strutted stents
implies an adjusted risk reduction of 56% for angiographic
restenosis. The restenosis rate observed in the thin group
was lower, even when there was a higher percentage of
diabetic patients and a longer final stent length, both of
which are well-known unfavorable factors of the long-term
outcome, especially in small vessels (1,2). The lesions in the
thick group were predisposed to restenosis by being more
Figure 1. Restenosis rates in lesions treated with a stent with a strut
thickness of 0.10 mm (thin group; open bar) and a stent with a strut
thickness of 0.10 mm (thick group; solid bar).
Table 3. Predictors of Restenosis in the Entire Study Group, as Assessed by Univariate and Multivariable Analyses
Variable
Restenosis Rate (%) Univariate Analysis Multivariable Analysis
Factor
Present
Factor
Absent
Chi-Square
Statistic
p
Value
Odds Ratio
(95% CI)
Chi-Square
Statistics
p
Value
Odds Ratio
(95% CI)
Stent length 16 mm 38.5 27.6 9.14  0.001 1.64 (1.24–2.16) 19.61 0.001 1.03 (1.01–1.04)
Strut thickness 0.10 mm 27.4 34.6 5.33 0.009 1.44 (1.09–1.90) 4.65 0.001 1.68 (1.23–2.29)
Diabetes mellitus 45.5 31.2 5.68 0.017 1.84 (1.10–3.04) 8.25 0.007 2.10 (1.21–3.68)
Age 60 yrs 31.8 28.6 5.69 0.017 1.40 (1.06–1.84) 0.1
Ostial lesion 42.4 31.3 4.34 0.037 1.61 (1.03–2.54) 0.1
Lesion type B2/C 34.4 28 3.86 0.049 1.35 (1.00–1.82) 0.1
Inflation pressure 14 atm 29.9 37.9 5.47 0.019 0.67 (0.52–0.94) 0.1
For continuous variables (i.e., age, stent length and inflation pressure), the median value was used as a cut-off point to define the two subgroups with the characteristic (i.e.,
restenosis) present or absent. Stepwise regression analysis was performed by putting into the model all the variables significant in the univariate analysis. Variables not significant
at the 0.1 level were deleted from the model.
CI  confidence interval.
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complex, longer and more commonly located in the ostium.
The favorable effect of thin struts was clinically apparent
only in vessels with a reference diameter between 2.76 and
2.99 mm. The loss index was significantly lower for stents
implanted in vessels that were 2.76 to 2.99 mm (Fig. 3),
despite no difference in relative gain (Table 4). The fact that
no advantage was found in very small vessels supports the
concept that the modest benefit obtained by stents with a
thin strut cannot override the small residual lumen present
in very small vessels. This may be due to the relatively high
metal/vessel ratio present when a stent is implanted in a
small vessel.
Small artery size, as assessed by angiography, is an
independent risk factor for the occurrence of restenosis and
MACE at follow-up after stent implantation (1–3). The
proposed mechanisms of such an unfavorable outcome are:
1) a high degree of vessel stretch and injury; 2) a small
postprocedural lumen; and 3) a high metal density. Vascular
injury and foreign body reaction are important mechanisms
by which stent implantation can provoke neointimal hyper-
Table 4. Angiographic and Procedural Characteristics of the Three Subgroups (Tertiles) According to Vessel Reference Diameter in
the Thin and Thick Groups
<2.50 mm VD 2.50–2.75 mm VD 2.76–2.99 mm VD
Thin Group
(n  155)
Thick Group
(n  145)
Thin Group
(n  154)
Thick Group
(n  137)
Thin Group
(n  200)
Thick Group
(n  150)
Vessel size (mm) 2.23  0.22 2.20  0.24 2.65  0.09 2.64  0.06 2.88  0.05 2.90  0.07
MLD (mm)
Before stenting 0.81  0.34 0.83  0.29 0.85  0.43 0.97  0.37 0.86  0.36 0.90  0.44*
After stenting 2.28  0.52 2.26  0.47* 2.64  0.40 2.63  0.39 2.90  0.42 2.90  0.48
Follow-up 1.51  0.72 1.53  0.68 1.69  0.78 1.56  0.75* 2.02  0.80 1.67  0.73*
DS (%)
Before stenting 63  15 62  12 66  16 63  14 66  12 65  15
After stenting 0  3.62 0  3.08 1.00  6.05 0.79  5.02 0  4.45 1.00  8.63
Follow-up 39  22 38  24 38  26 43  26 31  25 40  24*
Restenosis rate (%) 31.8 34.9 32 37.9 23.5 37*
Acute gain 1.90  0.51 1.94  0.44 2.14  0.59 1.99  1.47 2.32  0.49 2.11  0.64*
Relative gain 0.85  0.21 0.90  0.22 0.81  0.22 0.76  0.18* 0.80  0.17 0.76  0.22
Late loss 1.05  0.76 1.18  1.72* 1.12  0.83 1.25  0.75 1.12  0.88 1.50  1.74*
Loss index 0.56  0.40 0.62  0.39 0.57  0.47 0.64  0.38 0.48  0.37 0.78  0.37*
Lesion length (mm) 10  6 11  6 10  7 11  6 10  6 11  9
Stent length (mm) 19  13 18  8 21  12 19  12 22  13 18  8
Pressure inflation (atm) 16  3 14  3* 16  3 15  3* 15  3 15  3
BA ratio 1.4  0.2 1.4  0.2 1.3  0.1 1.2  0.1 1.2  0.1 1.1  0.2
*p  0.05 for comparisons between groups (thin and thick) within the same reference vessel diameter range. Data are presented as the mean value  SD.
BA  balloon-to-artery; DS  diameter stenosis; MLD  minimal lumen diameter; VD  vessel diameter.
Table 5. Main and Subgroup Analysis of Angiographic Data Obtained by a Mixed Linear Model With Group, Diameter and Group
 Diameter Interaction and Fixed Effects
Between
Groups
Between
Diameters
Interaction
Group 
Diameter
Thin Group vs.
Thick  Diameter
<2.50 mm
Thin Group vs.
Thick  Diameter
<2.51–2.75 mm
Thin Group vs.
Thick  Diameter
2.76–2.99 mm
MLD
Before stenting 0.005 0.001 0.043 — — 0.16  0.04 (0.001)
After stenting 0.73 0.001 0.006 — — —
Follow-up 0.03 0.001 0.007 — — 0.29  0.08 (0.001)
DS (%)
Before stenting 0.030 0.015 0.069 — — 5.12  1.54 (0.003)
After stenting 0.001 0.17 0.007 — 2.83  1.05 (0.020) 3.73  0.93 (0.001)
Follow-up 0.019 0.018 0.055 — — 7.46  2.53 (0.009)
Acute gain 0.004 0.001 0.008 — — 0.23  0.06 (0.001)
Relative gain 0.001 0.001 0.11 — — 0.08  0.02 (0.001)
Late loss 0.056 0.17 0.43 — — —
Loss index 0.007 0.027 0.28 — — 0.01  0.05 (0.015)
Stent length 0.49 0.003 0.55 — — —
Pressure inflation 0.001 0.094 0.018 1.10  0.34 (0.004) 1.47  0.35 (0.001) —
BA ratio 0.001 0.001 0.43 0.07  0.01 (0.001) 0.05  0.01 (0.018) 0.04  0.01 (0.035)
P values obtained from the mixed linear model analysis of angiographic data, together with the significant estimated group (thin and thick) differences standard error and Tukey
adjusted p values (in parentheses) for each subgroup (according to the reference vessel diameter 2.50, 2.51–2.75 and 2.76–2.99 mm) analysis. For the subgroup analyses, only
statistically significant results (p  0.05) are reported.
Abbreviations as in Table 4.
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plasia (14–16). Understanding the factors involved in vas-
cular injury imposed during stent deployment might allow
optimization of the stent design (e.g., stent/strut geometry
and stent material) to reduce restenosis.
A number of stent configurations are now available.
Differences have been reported in flexibility, tracking ability,
expansion, radiovisibility, side-branch access and resistance
to compression and recoil. Four different direct comparisons
of first-generation Palmaz-Schatz slotted-tube stents and
second-generation stents have been made (“stent vs. stent”
equivalency trials). In three studies (17–19), there were no
significant differences in restenosis at follow-up, including
MLD, percent DS, late loss and the binary restenosis rate.
Randomized trials often include selected patients who are
generally not representative of “real-life” stenting. Selected
subsets may lead to equalization of outcomes and mask
differences among the devices being tested (20).
Strut thickness and vessel damage. Kastrati et al. (9)
recently demonstrated that the use of a device with a thinner
strut is associated with a significant reduction in angio-
graphic and clinical restenosis after coronary artery stenting
in vessels2.8 mm in reference diameter. The adjusted risk
of restenosis associated with the thin-strutted stent was 0.42
(95% CI 0.26 to 0.68). One mechanism of stent-induced
damage is strut-imposed vascular injury, which corresponds
the extent of intimal thickening in experimental animals
(14,21–23). The struts of the expanding stent impose focal,
deep vascular trauma in comparison to the less controlled
stretching and fracturing of the vessel wall caused by balloon
inflation alone (23). In addition to the deep injury associated
with stent expansion, more superficial vascular injury occurs
during stent expansion in areas removed from stent struts
themselves. Furthermore, Rogers et al. (15) demonstrated
that, using stents with a similar total surface area and strut
thickness but a different geometric configuration, the stent
design in which the struts created a more complex and
closed area (corrugated-ring design) permitted 33% less
injury in the spaces bounded by each strut, as compared with
the stent design in which the inter-strut areas were more
simple and open in shape (slotted-tube design).
Study limitations. This is a nonrandomized, retrospective
study. Furthermore, the rate angiographic follow-up was
low. However, it was similar in the two groups (56% in the
thin group vs. 57% thick group; p  0.80); therefore, any
potential selection bias should be equally distributed in the
two groups.
Conclusions. This study supports the concept that strut
thickness is an independent predictor of angiographic reste-
nosis in coronary arteries with a reference diameter of 2.76
Figure 2. Restenosis rates in lesions treated with a stent with a strut thickness of0.10 mm (thin group; open bars) and a stent with a strut thickness0.10
mm (thick group; solid bars), according to the reference vessel diameter (2.50, 2.51 to 2.75 and 2.76 to 2.99 mm).
Figure 3. The loss index according to the vessel reference (2.50, 2.51 to
2.75 and 2.76 to 2.99 mm) in lesions treated with a stent with a strut
thickness 0.10 mm (solid diamonds on continuous line) and a stent
with a strut thickness 0.10 mm (open squares on dotted line).
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to 2.99 mm. Even with the availability of drug-eluting
stents, which seem to drastically reduce the restenosis rate,
the result of the present study may contribute to a further
reduction in the restenosis rate after stent implantation in
small coronary arteries.
Reprint requests and correspondence: Dr. Antonio Colombo,
EMO Centro Cuore Columbus, Via Buonarroti 48, 20145 Milan,
Italy. E-mail: columbus@micronet.it.
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